Hemispherx BioPharma (NYSEAMERICAN: HEB) Plans Follow-Up Clinical Study for Avian Influenza Treatment

Hemispherx BioPharma (NYSEAMERICAN: HEB) Plans Follow-Up Clinical Study for Avian Influenza Treatment

On February 7, 2025, Hemispherx BioPharma, operating under AIM ImmunoTech Inc., made public its intentions to conduct a follow-up clinical study to assess a combined treatment approach for avian influenza outbreaks. The study will involve AIM’s Ampligen® along with AstraZeneca’s FluMist®. A detailed press release outlining this initiative has been included in the recent Form 8-K filing as Exhibit 99.1. The proposed clinical trial follows previou…

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo - BioTuesdays

AIM ImmunoTech (NYSE:AIM) has announced plans for a follow-up clinical study to evaluate the potential avian influenza combination therapy of its Ampligen with Astra Zeneca’s (NASDAQ: AZN) FluMist. According to AIM, the proposed trial builds on prior research that the company has sponsored at the University of Alabama-Birmingham, which demonstrated that intranasal administration of Ampligen following the intranasal delivery of the FluMist season…